PML represses lung cancer metastasis by suppressing the nuclear EGFR-mediated transcriptional activation of MMP2

References

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90; PMID:21296855; http://dx.doi.org/10.3322/caac.20107
   PubMed Web of Science ®Google Scholar
• Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006; 12:895-904; PMID: 16892035; http://dx.doi.org/10.1038/nm1469
   PubMed Web of Science ®Google Scholar
• Guo CB, Wang S, Deng C, Zhang DL, Wang FL, Jin XQ. Relationship between matrix metalloproteinase 2 and lung cancer progression. Mol Diagn Ther 2007; 11:183-92; PMID:17570740; http://dx.doi.org/10.1007/BF03256240
   PubMed Web of Science ®Google Scholar
• Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006; 25:9-34; PMID:16680569; http://dx.doi.org/10.1007/s10555-006-7886-9
   PubMed Web of Science ®Google Scholar
• Reineke EL, Kao HY. PML: an emerging tumor suppressor and a target with therapeutic potential. Cancer Ther 2009; 7:219-26; PMID:19756257
   PubMedGoogle Scholar
• Gurrieri C, Capodieci P, Bernardi R, Scaglioni PP, Nafa K, Rush LJ, Verbel DA, Cordon-Cardo C, Pandolfi PP. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst 2004; 96:269-79; PMID:14970276; http://dx.doi.org/10.1093/jnci/djh043
   PubMedGoogle Scholar
• Li Q, He Y, Wei L, Wu X, Wu D, Lin S, Wang Z, Ye Z, Lin SC. AXIN is an essential co-activator for the promyelocytic leukemia protein in p53 activation. Oncogene 2011; 30:1194-204; PMID:21057547; http://dx.doi.org/10.1038/onc.2010.499
   PubMed Web of Science ®Google Scholar
• Vannucchi S, Percario ZA, Chiantore MV, Matarrese P, Chelbi-Alix MK, Fagioli M, Pelicci PG, Malorni W, Fiorucci G, Romeo G, et al. Interferon-beta induces S phase slowing via up-regulated expression of PML in squamous carcinoma cells. Oncogene 2000; 19:5041-53; PMID:11042692; http://dx.doi.org/10.1038/sj.onc.1203883
   PubMed Web of Science ®Google Scholar
• Bernardi R, Guernah I, Jin D, Grisendi S, Alimonti A, Teruya-Feldstein J, Cordon-Cardo C, Simon MC, Rafii S, Pandolfi PP. PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature 2006; 442:779-85; PMID:16915281; http://dx.doi.org/10.1038/nature05029
   PubMed Web of Science ®Google Scholar
• Reineke EL, Liu Y, Kao HY. Promyelocytic leukemia protein controls cell migration in response to hydrogen peroxide and insulin-like growth factor-1. J Biol Chem 2010; 285:9485-92; PMID:20100838; http://dx.doi.org/10.1074/jbc.M109.063362
   PubMed Web of Science ®Google Scholar
• Yuan WC, Lee YR, Huang SF, Lin YM, Chen TY, Chung HC, Tsai CH, Chen HY, Chiang CT, Lai CK, et al. A Cullin3-KLHL20 Ubiquitin ligase-dependent pathway targets PML to potentiate HIF-1 signaling and prostate cancer progression. Cancer Cell 2011; 20:214-28; PMID:21840486; http://dx.doi.org/10.1016/j.ccr.2011.07.008
   PubMed Web of Science ®Google Scholar
• Zhou W, Bao S. PML-mediated signaling and its role in cancer stem cells. Oncogene 2013; 33:1475-84; PMID:23563177; http://dx.doi.org/10.1038/onc.2013.111
   PubMed Web of Science ®Google Scholar
• Wang SC, Nakajima Y, Yu YL, Xia W, Chen CT, Yang CC, McIntush EW, Li LY, Hawke DH, Kobayashi R, et al. Tyrosine phosphorylation controls PCNA function through protein stability. Nat Cell Biol 2006; 8:1359-68; PMID:17115032
   PubMed Web of Science ®Google Scholar
• Liccardi G, Hartley JA, Hochhauser D. EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. Cancer Res 2011; 71:1103-14; PMID:21266349; http://dx.doi.org/10.1158/0008-5472.CAN-10-2384
   PubMed Web of Science ®Google Scholar
• Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Kehlbach R, Rodemann HP. Nuclear EGFR shuttling induced by ionizing radiation is regulated by phosphorylation at residue Thr654. FEBS Lett 2010; 584:3878-84; PMID:20692258; http://dx.doi.org/10.1016/j.febslet.2010.08.005
   PubMed Web of Science ®Google Scholar
• Hsu SC, Miller SA, Wang Y, Hung MC. Nuclear EGFR is required for cisplatin resistance and DNA repair. Am J Transl Res 2009; 1:249-58; PMID:19956435
   PubMed Web of Science ®Google Scholar
• Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 2009; 28:3801-13; PMID:19684613; http://dx.doi.org/10.1038/onc.2009.234
   PubMed Web of Science ®Google Scholar
• Huang WC, Chen YJ, Li LY, Wei YL, Hsu SC, Tsai SL, Chiu PC, Huang WP, Wang YN, Chen CH, et al. Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells. J Biol Chem 2011; 286:20558-68; PMID:21487020; http://dx.doi.org/10.1074/jbc.M111.240796
   PubMed Web of Science ®Google Scholar
• Lee PC, Lee HJ, Kakadiya R, Sanjiv K, Su TL, Lee TC. Multidrug-resistant cells overexpressing P-glycoprotein are susceptible to DNA crosslinking agents due to attenuated Src/nuclear EGFR cascade-activated DNA repair activity. Oncogene 2012; 32:1144-54; PMID:22525278; http://dx.doi.org/10.1038/onc.2012.133
   PubMed Web of Science ®Google Scholar
• Yu YL, Chou RH, Wu CH, Wang YN, Chang WJ, Tseng YJ, Chang WC, Lai CC, Lee HJ, Huo L, et al. Nuclear EGFR suppresses ribonuclease activity of polynucleotide phosphorylase through DNAPK-mediated phosphorylation at serine 776. J Biol Chem 2012; 287:31015-26; PMID:22815474; http://dx.doi.org/10.1074/jbc.M112.358077
   PubMed Web of Science ®Google Scholar
• Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, Bourguignon L, Hung MC. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 2001; 3:802-8; PMID:11533659
   PubMed Web of Science ®Google Scholar
• Lo HW, Hsu SC, Ali-Seyed M, Gunduz M, Xia W, Wei Y, Bartholomeusz G, Shih JY, Hung MC. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 2005; 7:575-89; PMID:15950906; http://dx.doi.org/10.1016/j.ccr.2005.05.007
   PubMed Web of Science ®Google Scholar
• Hanada N, Lo HW, Day CP, Pan Y, Nakajima Y, Hung MC. Co-regulation of B-Myb expression by E2F1 and EGF receptor. Mol Carcinog 2006; 45:10-7; PMID:16299810; http://dx.doi.org/10.1002/mc.20147
   PubMed Web of Science ®Google Scholar
• Huo L, Wang YN, Xia W, Hsu SC, Lai CC, Li LY, Chang WC, Wang Y, Hsu MC, Yu YL, et al. RNA helicase A is a DNA-binding partner for EGFR-mediated transcriptional activation in the nucleus. Proc Natl Acad Sci U S A 2010; 107:16125-30; PMID:20802156; http://dx.doi.org/10.1073/pnas.1000743107
   PubMed Web of Science ®Google Scholar
• Xia W, Wei Y, Du Y, Liu J, Chang B, Yu YL, Huo LF, Miller S, Hung MC. Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol Carcinog 2009; 48:610-7; PMID:19058255; http://dx.doi.org/10.1002/mc.20504
   PubMed Web of Science ®Google Scholar
• Hadzisejdic I, Mustac E, Jonjic N, Petkovic M, Grahovac B. Nuclear EGFR in ductal invasive breast cancer: correlation with cyclin-D1 and prognosis. Mod Pathol 2010; 23:392-403; PMID:20062009; http://dx.doi.org/10.1038/modpathol.2009.166
   PubMed Web of Science ®Google Scholar
• Wang YN, Wang H, Yamaguchi H, Lee HJ, Lee HH, Hung MC. COPI-mediated retrograde trafficking from the Golgi to the ER regulates EGFR nuclear transport. Biochem Biophys Res Commun 2010; 399:498-504; PMID:20674546; http://dx.doi.org/10.1016/j.bbrc.2010.07.096
   PubMed Web of Science ®Google Scholar
• Hsu SC, Hung MC. Characterization of a novel tripartite nuclear localization sequence in the EGFR family. J Biol Chem 2007; 282:10432-40; PMID:17283074; http://dx.doi.org/10.1074/jbc.M610014200
   PubMed Web of Science ®Google Scholar
• Wang YN, Yamaguchi H, Hsu JM, Hung MC. Nuclear trafficking of the epidermal growth factor receptor family membrane proteins. Oncogene 2010; 29:3997-4006; PMID:20473332; http://dx.doi.org/10.1038/onc.2010.157
   PubMed Web of Science ®Google Scholar
• Wang YN, Yamaguchi H, Huo L, Du Y, Lee HJ, Lee HH, Wang H, Hsu JM, Hung MC. The translocon Sec61beta localized in the inner nuclear membrane transports membrane-embedded EGF receptor to the nucleus. J Biol Chem 2010; 285:38720-9; PMID:20937808; http://dx.doi.org/10.1074/jbc.M110.158659
   PubMed Web of Science ®Google Scholar
• Iida M, Brand TM, Campbell DA, Li C, Wheeler DL. Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor. Oncogene 2012; 32:759-67; PMID:22430206; http://dx.doi.org/10.1038/onc.2012.90
   PubMed Web of Science ®Google Scholar
• Li C, Iida M, Dunn EF, Wheeler DL. Dasatinib blocks cetuximab- and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma. Radiother Oncol 2010; 97:330-7; PMID:20667610; http://dx.doi.org/10.1016/j.radonc.2010.06.010
   PubMed Web of Science ®Google Scholar
• Brand TM, Iida M, Dunn EF, Luthar N, Kostopoulos KT, Corrigan KL, Wleklinski MJ, Yang D, Wisinski KB, Salgia R, et al. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer. Mol Cancer Ther 2014; 13:1356-1368.
   PubMed Web of Science ®Google Scholar
• Du Y, Shen J, Hsu JL, Han Z, Hsu MC, Yang CC, Kuo HP, Wang YN, Yamaguchi H, Miller SA, et al. Syntaxin 6-mediated Golgi translocation plays an important role in nuclear functions of EGFR through microtubule-dependent trafficking. Oncogene 2014; 33:756-70; PMID:23376851; http://dx.doi.org/10.1038/onc.2013.1
   PubMed Web of Science ®Google Scholar
• Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305:1163-7; PMID:15284455; http://dx.doi.org/10.1126/science.1101637
   PubMed Web of Science ®Google Scholar
• Leinonen T, Pirinen R, Bohm J, Johansson R, Kosma VM. Increased expression of matrix metalloproteinase-2 (MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer. Histol Histopathol 2008; 23:693-700; PMID:18366007
   PubMed Web of Science ®Google Scholar
• Xu M, Wang YZ. miR133a suppresses cell proliferation, migration and invasion in human lung cancer by targeting MMP14. Oncol Rep 2013; 30:1398-404; PMID:23783274
   PubMed Web of Science ®Google Scholar
• Zheng S, Chang Y, Hodges KB, Sun Y, Ma X, Xue Y, Williamson SR, Lopez-Beltran A, Montironi R, Cheng L. Expression of KISS1 and MMP-9 in non-small cell lung cancer and their relations to metastasis and survival. Anticancer Res 2010; 30:713-8; PMID:20392988
   PubMed Web of Science ®Google Scholar
• Wang XM, Li J, Yan MX, Liu L, Jia DS, Geng Q, Lin HC, He XH, Li JJ, Yao M. Integrative analyses identify osteopontin, LAMB3 and ITGB1 as critical pro-metastatic genes for lung cancer. PLoS One 2013; 8:e55714; PMID:23441154; http://dx.doi.org/10.1371/journal.pone.0055714
   PubMed Web of Science ®Google Scholar
• Kuo HY, Chen YC, Chang HY, Jeng JC, Lin EH, Pan CM, Chang YW, Wang ML, Chou YT, Shih HM, et al. The PML isoform IV is a negative regulator of nuclear EGFR's transcriptional activity in lung cancer. Carcinogenesis 2013; 34:1708-16; PMID:23563092; http://dx.doi.org/10.1093/carcin/bgt109
   PubMed Web of Science ®Google Scholar
• Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R, Huang S. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 2004; 23:3550-60; PMID:15116091; http://dx.doi.org/10.1038/sj.onc.1207383
   PubMed Web of Science ®Google Scholar
• Stadler M, Chelbi-Alix MK, Koken MH, Venturini L, Lee C, Saib A, Quignon F, Pelicano L, Guillemin MC, Schindler C, et al. Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element. Oncogene 1995; 11:2565-73; PMID:8545113
   PubMed Web of Science ®Google Scholar
• Traynor AM, Weigel TL, Oettel KR, Yang DT, Zhang C, Kim K, Salgia R, Iida M, Brand TM, Hoang T, et al. Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer. Lung Cancer 2013; 81:138-41; PMID:23628526; http://dx.doi.org/10.1016/j.lungcan.2013.03.020
   PubMed Web of Science ®Google Scholar
• Huang W, Yu LF, Zhong J, Wu W, Zhu JY, Jiang FX, Wu YL. Stat3 is involved in angiotensin II-induced expression of MMP2 in gastric cancer cells. Dig Dis Sci 2009; 54:2056-62; PMID:19082717; http://dx.doi.org/10.1007/s10620-008-0617-z
   PubMed Web of Science ®Google Scholar
• Kawasaki A, Matsumura I, Kataoka Y, Takigawa E, Nakajima K, Kanakura Y. Opposing effects of PML and PML/RAR alpha on STAT3 activity. Blood 2003; 101:3668-73; PMID:12506013; http://dx.doi.org/10.1182/blood-2002-08-2474
   PubMed Web of Science ®Google Scholar
• Hubackova S, Krejcikova K, Bartek J, Hodny Z. Interleukin 6 signaling regulates promyelocytic leukemia protein gene expression in human normal and cancer cells. J Biol Chem 2012; 287:26702-14; PMID:22711534; http://dx.doi.org/10.1074/jbc.M111.316869
   PubMed Web of Science ®Google Scholar
• Viti J, Feathers A, Phillips J, Lillien L. Epidermal growth factor receptors control competence to interpret leukemia inhibitory factor as an astrocyte inducer in developing cortex. J Neurosci 2003; 23:3385-93; PMID:12716946
   PubMed Web of Science ®Google Scholar
• Arnason BG. Immunologic therapy of multiple sclerosis. Annu Rev Med 1999; 50:291-302; PMID:10073279; http://dx.doi.org/10.1146/annurev.med.50.1.291
   PubMed Web of Science ®Google Scholar
• Galboiz Y, Shapiro S, Lahat N, Miller A. Modulation of monocytes matrix metalloproteinase-2, MT1-MMP and TIMP-2 by interferon-gamma and -beta: implications to multiple sclerosis. J Neuroimmunol 2002; 131:191-200; PMID:12458052; http://dx.doi.org/10.1016/S0165-5728(02)00266-7
   PubMed Web of Science ®Google Scholar
• Ling X, Marini F, Konopleva M, Schober W, Shi Y, Burks J, Clise-Dwyer K, Wang RY, Zhang W, Yuan X, et al. Mesenchymal stem cells overexpressing IFN-beta inhibit breast cancer growth and metastases through Stat3 signaling in a syngeneic Tumor model. Cancer Microenviron 2010; 3:83-95; PMID:21209776; http://dx.doi.org/10.1007/s12307-010-0041-8
   PubMedGoogle Scholar
• Qin H, Moellinger JD, Wells A, Windsor LJ, Sun Y, Benveniste EN. Transcriptional suppression of matrix metalloproteinase-2 gene expression in human astroglioma cells by TNF-alpha and IFN-gamma. J Immunol 1998; 161:6664-73; PMID:9862695
   PubMed Web of Science ®Google Scholar
• Guan D, Factor D, Liu Y, Wang Z, Kao HY. The epigenetic regulator UHRF1 promotes ubiquitination-mediated degradation of the tumor-suppressor protein promyelocytic leukemia protein. Oncogene 2013; 32:3819-28; PMID:22945642; http://dx.doi.org/10.1038/onc.2012.406
   PubMed Web of Science ®Google Scholar
• Park MY, Kim DR, Jung HW, Yoon HI, Lee JH, Lee CT. Genetic immunotherapy of lung cancer using conditionally replicating adenovirus and adenovirus-interferon-beta. Cancer Gene Ther 2010; 17:356-64; PMID:19893592; http://dx.doi.org/10.1038/cgt.2009.78
   PubMed Web of Science ®Google Scholar
• Chu YW, Yang PC, Yang SC, Shyu YC, Hendrix MJ, Wu R, Wu CW. Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am J Respir Cell Mol Biol 1997; 17:353-60; PMID:9308922; http://dx.doi.org/10.1165/ajrcmb.17.3.2837
   PubMed Web of Science ®Google Scholar
• Chou YT, Lin HH, Lien YC, Wang YH, Hong CF, Kao YR, Lin SC, Chang YC, Lin SY, Chen SJ, et al. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. Cancer Res 2010; 70:8822-31; PMID:20978205; http://dx.doi.org/10.1158/0008-5472.CAN-10-0638
   PubMed Web of Science ®Google Scholar